Gain Therapeutics to Present at the 38th Annual ROTH Conference
MWN-AI** Summary
Gain Therapeutics, Inc. (Nasdaq: GANX), a leading clinical-stage biotechnology firm, is set to participate in the 38th Annual ROTH Conference, scheduled for March 22-24, 2026, in Dana Point, California. Gene Mack, the Company’s President and CEO, will engage in a fireside chat on March 23 at 11:30 a.m. PT, where attendees can access a live webcast or replay via Gain's official website.
Gain Therapeutics focuses on the innovation of allosteric small molecule therapies, with its flagship drug candidate, GT-02287, currently undergoing evaluation for Parkinson's disease in a Phase 1b clinical trial. This candidate also shows promise for treating additional conditions such as Gaucher's disease, dementia with Lewy bodies, and Alzheimer’s disease. The Company boasts a range of preclinical assets aimed at targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Utilizing its proprietary Magellan™ platform, Gain accelerates drug discovery processes to develop novel, modulating treatments for challenging and often untreatable conditions, including various neurodegenerative diseases and rare genetic disorders.
The release includes forward-looking statements that reflect Gain's management outlook on product development timelines and regulatory submissions, emphasizing potential risks and uncertainties associated with these projections. As per standard practice, these statements are qualified by cautionary notes urging stakeholders not to place excessive reliance on their accuracy, as actual results may differ significantly.
For those interested in scheduling meetings with Gain’s management during the conference, contact can be made through various means as provided in the original release.
In summary, Gain Therapeutics continues to position itself as a front-runner in developing novel therapies with high potential in serious diseases, drawing attention during the forthcoming ROTH Conference.
MWN-AI** Analysis
Gain Therapeutics, Inc. (Nasdaq: GANX), is preparing for a significant spotlight at the upcoming 38th Annual ROTH Conference, which could be a pivotal moment for investors and stakeholders. The conference will feature a fireside chat led by Gene Mack, offering vital insights into the company’s ongoing projects and future potential.
Currently, Gain is in the critical Phase 1b trial for its lead candidate, GT-02287, targeting Parkinson’s disease and potentially other neurodegenerative conditions. The company’s approach—utilizing its proprietary Magellan™ platform—positions it strategically in the emerging field of allosteric small molecule therapies, which have shown promise in modulating complex diseases.
For investors, the ROTH Conference represents an opportunity to gauge management's strategic vision and updated timelines regarding clinical trials and regulatory submissions. Given that Gain is focused on treating significant unmet medical needs, there lies an inherent upside potential if GT-02287 achieves positive trial results or gains FDA approval.
However, investors should remain aware of inherent risks, including the typical volatility associated with biotechnology stocks and the uncertainties surrounding clinical trial outcomes. Forward-looking statements made at the conference should be taken with a cautionary outlook, as the evolution of drug development is fraught with challenges.
In light of this, a prudent investment decision would involve closely monitoring the outcomes from the Phase 1b clinical trials and maintaining a diversified portfolio to mitigate risk. For those already invested in Gain Therapeutics, attending the ROTH Conference (virtually or in person) can provide deeper insights and allow for data-informed decisions. For prospective investors, maintaining vigilance around upcoming trial results and overall market trends will be crucial when considering entry points into Gain’s stock.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BETHESDA, Md., March 19, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference, being held March 22-24, 2026, in Dana Point, CA.
Fireside Chat Details
Date: Monday, March 23, 2026
Time: 11:30 a.m. PT
Access a live webcast or a replay of the fireside chat here or visit the “Investors & Media/News & Events” section of the Company’s website at https://gaintherapeutics.com.
If you are unable to attend the conference and would like to schedule a meeting with Gain management, please contact either your ROTH representative or ir@gaintherapeutics.com.
About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain’s lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson’s disease with or without a GBA1 mutation in a Phase 1b clinical trial. GT-02287 has further potential in Gaucher’s disease, dementia with Lewy bodies, and Alzheimer’s disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors.
Gain’s unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
Forward-Looking Statements
This release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as “believes,” “expects,” “anticipates,” “intends,” “will,” “may,” “should,” or similar expressions. These forward-looking statements reflect management’s current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding: the development of the Company’s current or future product candidates including GT-02287 and GT-04686; expectations regarding the completion and timing of results from a Phase 1b clinical study for GT-02287, including any extension studies; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287, including any extension studies; the timing of any submissions to the FDA or other regulatory bodies and agencies and the timing of any responses from the FDA or other regulatory bodies and agencies; the timing of the commencement of any Phase 2 clinical studies for GT-02287; and the potential therapeutic and clinical benefits of the Company’s product candidates, including GT-02287 and GT-04686. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, please refer to the Company’s Form 10-K for the year ended December 31, 2024, and other filings made with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether because of new information, future events or otherwise.
Investors:
Gain Therapeutics, Inc.
Apaar Jammu
Director, Investor Relations and Public Relations
ajammu@gaintherapeutics.com
LifeSci Advisors LLC
Chuck Padala
Managing Director
chuck@lifesciadvisors.com
Media:
Russo Partners LLC
Nic Johnson and Elio Ambrosio
nic.johnson@russopartnersllc.com
elio.ambrosio@russopartnersllc.com
(760) 846-9256
FAQ**
How does Gain Therapeutics Inc. (GANX) plan to differentiate its allosteric small molecule therapies from existing treatments in the Parkinson's disease market during the upcoming ROTH Conference?
Can Gain Therapeutics Inc. (GANX) provide insights into the expected timeline for patient enrollment and results from the Phase 1b clinical study for GT-02287 at the ROTH Conference?
What challenges does Gain Therapeutics Inc. (GANX) foresee in the development and regulatory approval of its drug candidates, including GT-02287 and GT-04686, as discussed at the ROTH Conference?
How is Gain Therapeutics Inc. (GANX) utilizing its Magellan™ platform to accelerate drug discovery for neurodegenerative diseases, and what can investors expect in terms of progress during the ROTH Conference?
**MWN-AI FAQ is based on asking OpenAI questions about Gain Therapeutics Inc. (NASDAQ: GANX).
NASDAQ: GANX
GANX Trading
0.0% G/L:
$1.935 Last:
402,424 Volume:
$1.90 Open:
